Bausch + Lomb was valued at $6.48 billion in the company’s U.S. market debut on May 6 as the eye-care company’s shares opened nearly 3 percent above an offer price that was well below the targeted range.
Alcon is officially a standalone company. The eye care specialist officially spun out from Swiss pharma giant Novartis. Alcon began trading on the SIX Swiss Exchange and New York Stock Exchange under the symbol “ALC.”
